Healthcare analysts from Rodman and Renshow and Oppenheimer chimed in on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Incyte Corporation (NASDAQ:INCY), providing insights on …
Incyte Corporation (INCY:INCY) announced it has acquired the rights to develop and commercialize ruxolitinib (Jakafi®), its proprietary JAK1/JAK2 inhibitor, for graft-versus-host disease (GVHD) from …
Incyte Corporation (NASDAQ:INCY) and Eli Lilly and Company (NYSE:LLY) announced that detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib, a …
Incyte Corporation (NASDAQ:INCY) announced its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in combination with capecitabine for the second-line …
Analysts weigh in with bullish sentiments on both Incyte Corporation (NASDAQ:INCY) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) following the termination of the drug trial …
Incyte Corporation (NASDAQ:INCY) announced that the Phase 2 sub-study of ruxolitinib or placebo in combination with regorafenib in patients with relapsed or refractory metastatic …
Credit Suisse analyst Alethia Young came out today with new ratings and price targets on a handful of healthcare stocks. Let’s take a …
Incyte Corporation (NASDAQ:INCY) and Eli Lilly and Company (NYSE:LLY) announced that Lilly has submitted a new drug application (NDA) to the U.S.
Incyte Corporation (NASDAQ:INCY) reported significant and rapid progress in its continued transformation into a leading global biopharmaceutical company. With two new programs expected to …
Incyte Corporation (NASDAQ:INCY) and AstraZeneca plc (ADR) (NYSE:AZN) announced a new collaboration to evaluate the efficacy and safety of Incyte’s Janus-associated kinase (JAK) 1 …